Search Results
May 28, 2026, 10:01 ET Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | DelveInsight
clinical adoption of novel modalities, such as BAFF-R inhibitor (Novartis' Ianalumab), CXCR5 antagonist (Pfizer's PF-06835375), Anti-CD38 (Takeda's Mezagitamab), and others, are also fueling the growth of the ITP market.Aparna Thakur, Assistant Project Manager of Forecasting
More news about: DelveInsight Business Research, LLP
May 28, 2026, 09:07 ET CD Valet Launches Enhanced Tools to its Digital CD Marketplace, Helping Consumers Make the Most of their Savings
money."These enhanced tools – backed by CD Valet's comprehensive CD data – make the company the most inclusive, data‑rich and user‑friendly one‑stop‑shop for CD insights and decision making.About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks
More news about: CD Valet
May 28, 2026, 08:00 ET Blood Cancer United Data at 2026 ASCO and EHA Highlight Beat AML Progress, Patient Experience Insights and Access Barriers
VISPA-CEL, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B-Cell Non-HodgkinLymphoma (ANTLER Phase 1
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options."When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical
More news about: PeproMene Bio, Inc.
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options."When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical
More news about: PeproMene Bio, Inc.
May 28, 2026, 06:00 ET HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
pipeline.HanchorBio has built a pipeline of clinical and preclinical candidates, including HCB101, HCB301, HCB303, and HCB206. The Company's lead program, HCB101, is a CD47-targeting anti-cancer drug candidate designed through precision protein engineering to block tumor immune-evasion signals and restore macrophage-mediated
More news about: HanchorBio Inc.
May 28, 2026, 03:23 ET TestMu AI amplía KaneAI con funciones mejoradas de creación de pruebas y grabación avanzada
individuales, lo que mejora la resiliencia frente a problemas de ejecución intermitentes y reduce las ejecuciones manuales en grandes pipelines de CI/CD.«Las aplicaciones modernas son cada vez más dinámicas, interactivas y basadas en IA, lo que significa que los flujos de trabajo de pruebas también
More news about: TestMu AI (Formerly LambdaTest)
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform) and ImBiTDC (TDC Platform), which serve as the cornerstone
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
(pivekimab sunirine-pvzy) is a CD123-targeting ADC for the treatment of adult patients diagnosed with the hematological malignancy BPDCN. ADCs are designed to deliver potent cell death-inducing agents called 'payloads' directly to the cells expressing a specific protein. CD123 (IL-3Rα) is a protein overexpressed
More news about: AbbVie
May 27, 2026, 16:06 ET TestMu AI erweitert KaneAI um verbesserte Funktionen zur Testerstellung und erweiterte Aufzeichnungsmöglichkeiten
Dies verbessert die Ausfallsicherheit bei sporadisch auftretenden Ausführungsproblemen und reduziert manuelle Wiederholungsläufe in umfangreichen CI/CD-Pipelines.„Moderne Anwendungen werden immer dynamischer, interaktiver und KI-gesteuert, was bedeutet, dass auch Testabläufe anpassungsfähiger und
More news about: TestMu AI (Formerly LambdaTest)
May 27, 2026, 13:24 ET TestMu AI Expands KaneAI With Enhanced Test Authoring and Advanced Recording Capabilities
failures but also on individual test case failures, improving resilience against intermittent execution issues and reducing manual reruns in large-scale CI/CD pipelines."Modern applications are increasingly dynamic, interactive, and AI-driven, which means testing workflows also need to become more adaptive
More news about: TestMu AI (Formerly LambdaTest)
May 27, 2026, 13:19 ET TestMu AI Expands KaneAI With Enhanced Test Authoring and Advanced Recording Capabilities
failures but also on individual test case failures, improving resilience against intermittent execution issues and reducing manual reruns in large-scale CI/CD pipelines."Modern applications are increasingly dynamic, interactive, and AI-driven, which means testing workflows also need to become more adaptive
More news about: TestMu AI (Formerly LambdaTest)
May 27, 2026, 09:00 ET OCUDU Ecosystem Foundation Emerges as Key Hub for Open Source RAN Innovation with 21 New Global Member Organizations Since Launch
on enabling production-ready CU/DU implementations through open source collaboration. The foundation supports a full ecosystem approach, including CI/CD pipelines, interoperability testing, and deployment-ready blueprints to reduce complexity and accelerate time-to-market.With continued ecosystem
More news about: OCUDU Ecosystem Foundation
May 27, 2026, 08:00 ET Biohub releases a world model of protein biology
immunology research — EGFR and PDGFRβ (implicated in tumor growth), PD-L1 and CTLA-4 (immune checkpoints that cancer cells exploit to evade detection), and CD45 (a regulator of immune cell signaling). Designs achieved hit rates of 36–88% for compact minibinders and 15–29% for antibody-derived formats, with
More news about: Biohub
May 27, 2026, 07:30 ET Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
within the first one-month of dosing. Observed reductions in Gd-IgA1 were deeper than has been reported with BAFF/APRIL inhibitors, APRIL-inhibitors, and CD38 inhibitors at these early time points. Preliminary observations also demonstrated an increase in eGFR, decrease in spot UPCR, and a
More news about: Biohaven Ltd.
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
clinical benefit- Data from an ENSURE translational study demonstrated that BRII‑179-induced epitope-mismatched CD4+ T cells and HBs‑specific B cell maturation were associated with enhanced HBsAg loss following curative treatment, offering
More news about: Brii Biosciences Limited
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
(ER) 陽性、第 2 型人類表皮生長因子受體 (HER2) 陰性、ESR1 突變晚期或轉移性乳癌，並且在至少接受過一線內分泌治療後病情仍出現惡化的停經後女性或成年男性患者。 Stemline 亦在美國、歐洲及其他全球地區銷售他格索芙 (tagraxofusp-erzs)。這是一種針對 CD123 的新型標靶藥物，用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者，即侵襲性血液癌症。 此外，Stemline 在歐洲銷售 塞利尼索，這是一種用於治療多發性骨髓瘤的 XPO1 (出口蛋白 1) 抑制劑。 該公司亦分別針對乳癌及血液惡性腫瘤適應症，進行多項有關埃拉司群和他格索芙的適應症擴展研究，並且擁有龐大的臨床研發管線，當中包括多種處於不同開發階段、針對多種實體腫瘤和血液惡性腫瘤的其他候選藥物。
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
endocrina, negli Stati Uniti, in Europa e in altre regioni del mondo. Stemline commercializza anche tagraxofusp-erzs, una nuova terapia mirata diretta a CD123, per pazienti affetti da neoplasia a cellule dendritiche plasmacitoidi blastiche (BPDCN), un tumore ematologico aggressivo, negli Stati Uniti, in Europa
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
More news about: Hackensack Meridian John Theurer Cancer Center
May 26, 2026, 09:33 ET Lupus Research Alliance and Genentech Fund Researchers Translating CAR T Success into Durable Lupus Treatments
shown remarkable success in oncology and is now being studied in people with severe lupus. In ongoing clinical trials, some lupus patients treated with CD19-targeted CAR-T cells who had not responded to standard treatments experienced rapid, deep remission, allowing them to stop all other lupus medications.
More news about: Lupus Research Alliance
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
Groupの完全子会社であるStemline Therapeutics, Inc.（「Stemline」）は、コマーシャル・ステージにあるバイオ医薬品会社で、患者に革新的ながん治療を提供することに注力しています。Stemlineは、エストロゲン受容体（ER）陽性、ヒト上皮成長因子受容体2（HER2）陰性、ESR1遺伝子変異の進行・転移性乳がんで、少なくとも1ライン以上の内分泌療法後に病勢進行した閉経後女性または成人男性の治療を適応症とする経口内分泌療法剤エラセストラントを、米国、欧州をはじめとする世界各地で販売しています。また、Stemlineは、CD123に対する新規標的治療薬であるタグラクソフスプ・エルツを、ア
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations include several potentially practice-changing datasets across multiple tumor types.A pivotal highlight
More news about: Akeso, Inc.
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
2(HER2) 음성, ESR1 변이 진행성 또는 전이성 유방암을 앓는 폐경 후 여성 또는 성인 남성 치료에 적응증을 보유한 경구용 내분비 요법제다. 또한 스템라인은 미국, 유럽 및 기타 글로벌 지역에서 공격성 혈액암인 모구성 형질세포양 수지상세포 종양(BPDCN) 환자를 위한 CD123 표적 신규 표적치료제 타그락소푸스프-erzs를 상용화하고 있다. 이와 함께 스템라인은 유럽에서 다발골수종 치료용 XPO1 억제제 셀리넥서를 상용화하고 있다. 회사는 또한 유방암 및 혈액암 적응증에서 각각 엘라세스트란트와 타그락소푸스프의 다수 적응증 확대 연구를
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
terapia endocrina, en Estados Unidos, Europa y otras regiones del mundo. Stemline también comercializa tagraxofusp-erzs, una novedosa terapia dirigida a CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras
More news about: Menarini Industrie Farmaceutiche Riunite